FOURIER Presenter, Dr Marc Sabatine, Interviewed

Dr Mandrola gets the details on the PCSK9 inhibitor evolocumab, and asks the $64,000 (or is that $14,000) question about cost-effectiveness.

Source: Medscape Cardiology Podcast - March 24, 2017 Category: Cardiology Authors: Medscape Source Type: podcasts